Ingredient derived from bergamot and artichoke supports liver health, says recent study
A recently published randomized, double-blind, placebo-controlled trial found that supplementation with Bergacyn FF supports liver health and weight management.
Image courtesy of DolCas Biotech
A recently published randomized, double-blind, placebo-controlled trial1 found that supplementation with Bergacyn FF supports liver health and weight management. In the study, 86 subjects between the ages of 35 and 70 received either placebo or 300 mg/day Bergacyn FF for 12 weeks. Bergacyn FF is a formulation that contains Bergamot polyphenol fraction and Cynara Cardunculus extract. Because dietary changes and resultant weight loss are known to contribute to liver-fat regression, overweight and obese subjects in each group was given the task reducing their caloric intake by 400-500 calories per day.
Results showed that compared to placebo, those taking Bergacyn FF saw a 9% reduction in liver fat accumulation. In subjects over the age of 50, the reduction in liver fat was 15% greater than placebo. These changes were attributed solely to Bergacyn FF and not dietary changes. Another notable, and unexpected outcome was the ingredient’s impact on weight loss.
“The absolute difference made by Bergacyn FF for body weight reductions over placebo was approximately 4 lbs. The total weight loss in the Bergacyn FF group over 12 weeks fell just under 10 lbs,” explained Shavon Jackson-Michel, ND, director of Medical & Scientific Affairs of DolCas Biotech, in a press release. “The new research supports the traditional wisdom of botanical synergism and how standardized ingredient formulations could be the best way forward for multifactorial processes such as NAFL.”
Reference
- Ferro Y et al. “Randomized clinical trial: Bergamot citrus and wild cardoon reduce liver steatosis and body weight in non-diabetic individuals aged over 50 years.” Frontiers in Endocrinology, Published online ahead of print on August 11, 2020
